KPRX - KIORA PHARMACEUTICALS INC

2.4
-0.040   -1.667%

Share volume: 16,589
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$2.44
-0.04
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.76%
1 Month
16.50%
3 Months
14.29%
6 Months
-6.25%
1 Year
-25.00%
2 Year
-47.25%
Key data
Stock price
$2.40
P/E Ratio 
N/A
DAY RANGE
$2.39 - $2.45
EPS 
-$2.61
52 WEEK RANGE
$1.76 - $4.18
52 WEEK CHANGE
-$25.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.951 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.93
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$46,972
AVERAGE 30 VOLUME 
$1,377,500
Company detail
CEO: Brian M. Strem
Region: US
Website: kiorapharma.com
Employees: 10
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Recent news